Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia

Next Previous
Search
Trial Profile

Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tapentadol (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK

    • Most Recent Events

    • 25 Jun 2013 Actual initiation date changed from May 2010 to Jun 2010 as reported by ClinicalTrials.gov.
    • 01 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2011 Actual end date (April 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top